MA44762A - Sémaglutide utilisé dans le traitement de maladies cardiovasculaires - Google Patents
Sémaglutide utilisé dans le traitement de maladies cardiovasculairesInfo
- Publication number
- MA44762A MA44762A MA044762A MA44762A MA44762A MA 44762 A MA44762 A MA 44762A MA 044762 A MA044762 A MA 044762A MA 44762 A MA44762 A MA 44762A MA 44762 A MA44762 A MA 44762A
- Authority
- MA
- Morocco
- Prior art keywords
- semaglutide
- treatment
- cardiovascular diseases
- cardiovascular
- diseases
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 title 1
- 229950011186 semaglutide Drugs 0.000 title 1
- 108010060325 semaglutide Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16167458 | 2016-04-28 | ||
| EP16188262 | 2016-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44762A true MA44762A (fr) | 2019-03-06 |
Family
ID=58668875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044762A MA44762A (fr) | 2016-04-28 | 2017-04-28 | Sémaglutide utilisé dans le traitement de maladies cardiovasculaires |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20190134162A1 (fr) |
| EP (1) | EP3448416B1 (fr) |
| JP (1) | JP7221694B2 (fr) |
| KR (3) | KR20180135012A (fr) |
| CN (1) | CN109069589B (fr) |
| AU (2) | AU2017256774B2 (fr) |
| BR (1) | BR112018072020A2 (fr) |
| CA (1) | CA3022535A1 (fr) |
| CL (1) | CL2018003045A1 (fr) |
| DK (1) | DK3448416T3 (fr) |
| ES (1) | ES2928007T3 (fr) |
| HR (1) | HRP20221150T1 (fr) |
| HU (1) | HUE060040T2 (fr) |
| IL (1) | IL262390B1 (fr) |
| MA (1) | MA44762A (fr) |
| MX (1) | MX2018012700A (fr) |
| MY (1) | MY202967A (fr) |
| PH (1) | PH12018502274B1 (fr) |
| PL (1) | PL3448416T3 (fr) |
| RS (1) | RS63630B1 (fr) |
| RU (1) | RU2768283C2 (fr) |
| SI (1) | SI3448416T1 (fr) |
| WO (1) | WO2017186896A1 (fr) |
| ZA (2) | ZA202507394B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20221150T1 (hr) | 2016-04-28 | 2022-11-25 | Novo Nordisk A/S | Semaglutid u kardiovaskularnim stanjima |
| HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
| IL281938B2 (en) * | 2018-10-26 | 2024-04-01 | Novo Nordisk As | Stable semaglutide compositions and uses thereof |
| CN113194929B (zh) * | 2018-12-21 | 2022-12-09 | 诺和诺德股份有限公司 | Glp-1肽的喷雾干燥工艺 |
| MX2022009844A (es) * | 2020-02-18 | 2022-09-05 | Novo Nordisk As | Composiciones y usos del peptido similar al glucagon-1 (glp-1). |
| CN114699510B (zh) * | 2021-12-29 | 2024-07-16 | 浙江湃肽生物有限公司 | 一种司美格鲁肽微针阵列及其制备方法 |
| AU2023285400A1 (en) * | 2022-06-08 | 2024-12-05 | Zydus Lifesciences Limited | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management |
| CN117462654A (zh) * | 2023-09-28 | 2024-01-30 | 武汉大学人民医院（湖北省人民医院） | 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003226913A1 (en) | 2002-04-04 | 2003-10-20 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| AU2011249722B2 (en) * | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
| HRP20180425T1 (hr) * | 2010-12-16 | 2018-04-20 | Novo Nordisk A/S | Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline |
| US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN107266558A (zh) * | 2011-09-06 | 2017-10-20 | 诺沃—诺迪斯克有限公司 | Glp‑1衍生物 |
| JP6602760B2 (ja) | 2013-11-15 | 2019-11-06 | ノヴォ ノルディスク アー／エス | 選択的なｐｙｙ化合物及びその使用 |
| HRP20221150T1 (hr) | 2016-04-28 | 2022-11-25 | Novo Nordisk A/S | Semaglutid u kardiovaskularnim stanjima |
-
2017
- 2017-04-28 HR HRP20221150TT patent/HRP20221150T1/hr unknown
- 2017-04-28 KR KR1020187033310A patent/KR20180135012A/ko not_active Ceased
- 2017-04-28 BR BR112018072020-8A patent/BR112018072020A2/pt unknown
- 2017-04-28 US US16/097,032 patent/US20190134162A1/en active Pending
- 2017-04-28 CN CN201780026303.2A patent/CN109069589B/zh active Active
- 2017-04-28 PL PL17721109.1T patent/PL3448416T3/pl unknown
- 2017-04-28 DK DK17721109.1T patent/DK3448416T3/da active
- 2017-04-28 EP EP17721109.1A patent/EP3448416B1/fr active Active
- 2017-04-28 MX MX2018012700A patent/MX2018012700A/es unknown
- 2017-04-28 AU AU2017256774A patent/AU2017256774B2/en active Active
- 2017-04-28 MY MYPI2018703725A patent/MY202967A/en unknown
- 2017-04-28 RU RU2018140900A patent/RU2768283C2/ru active
- 2017-04-28 KR KR1020257007151A patent/KR20250038818A/ko active Pending
- 2017-04-28 PH PH1/2018/502274A patent/PH12018502274B1/en unknown
- 2017-04-28 MA MA044762A patent/MA44762A/fr unknown
- 2017-04-28 SI SI201731219T patent/SI3448416T1/sl unknown
- 2017-04-28 CA CA3022535A patent/CA3022535A1/fr active Pending
- 2017-04-28 RS RS20220901A patent/RS63630B1/sr unknown
- 2017-04-28 ES ES17721109T patent/ES2928007T3/es active Active
- 2017-04-28 JP JP2018556411A patent/JP7221694B2/ja active Active
- 2017-04-28 WO PCT/EP2017/060160 patent/WO2017186896A1/fr not_active Ceased
- 2017-04-28 HU HUE17721109A patent/HUE060040T2/hu unknown
- 2017-04-28 KR KR1020227036550A patent/KR102778218B1/ko active Active
-
2018
- 2018-10-15 IL IL262390A patent/IL262390B1/en unknown
- 2018-10-25 CL CL2018003045A patent/CL2018003045A1/es unknown
-
2024
- 2024-10-04 AU AU2024227113A patent/AU2024227113A1/en active Pending
-
2025
- 2025-01-15 US US19/023,039 patent/US20250288649A1/en active Pending
- 2025-05-02 US US19/197,677 patent/US20250262281A1/en active Pending
- 2025-09-03 ZA ZA2025/07394A patent/ZA202507394B/en unknown
- 2025-09-03 ZA ZA2025/07395A patent/ZA202507395B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279752B (en) | Polycyclic compounds and use thereof in the treatment of immune disorders | |
| MA44762A (fr) | Sémaglutide utilisé dans le traitement de maladies cardiovasculaires | |
| EP3370703A4 (fr) | Combinaison de gemcabène pour le traitement de maladies cardiovasculaires | |
| EP3390634A4 (fr) | Compositions et méthodes pour le traitement de maladies oculaires | |
| EP3359171C0 (fr) | Utilisation d'akkermansia muciniphila pour traiter des états inflammatoires | |
| EP3370748A4 (fr) | Microbiote thérapeutique pour le traitement et/ou la prévention de l'allergie alimentaire | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| SI3240554T1 (sl) | Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni | |
| EP3960735C0 (fr) | Dérivés de quinazoline utilisés pour traiter le vih | |
| MA39960A (fr) | Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| EP3448263A4 (fr) | Traitement électrothérapeutique | |
| EP3341391A4 (fr) | Compositions et procédés pour le traitement de la douleur | |
| PT3681857T (pt) | Fluorofenil-beta-hidroxietilaminas e sua utilização no tratamento de hiperglicemia | |
| HUE036084T2 (hu) | Buprenorfin dimer és alkalmazása gasztrointesztinális rendellenességek kezelésénél | |
| EP3503903A4 (fr) | Traitement ascaroside de maladies auto-immunes et inflammatoires | |
| MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
| HUE062784T2 (hu) | Indolinon vegyületek és alkalmazásuk fibrotikus betegségek kezelésében | |
| EP3344258A4 (fr) | Traitement de maladies auto-immunes et de maladies auto-inflammatoires | |
| EP3426307A4 (fr) | Utilisation de dreadd pour la modulation neuronale dans le traitement de maladies neuronales | |
| EP3431517A4 (fr) | Copolymère, et agent de traitement de surface | |
| MA47450A (fr) | Sulfinylpyridines et leur utilisation dans le traitement du cancer | |
| EP3395341A4 (fr) | Composition pour le traitement de maladies neuromotrices et son utilisation | |
| EP3678692A4 (fr) | Stratification du génotype dans le traitement et la prévention du diabète | |
| EP3848022C0 (fr) | Agent thérapeutique pour utilisation dans le traitement d'infections |